Product Name: XcellFect RNA Transfection Reagent Catalog No.: D7010101 Storage: Sealed at 4°C. Avoid repeated freeze-thaw cycles. Why Choose XcellFect? High Efficiency, Low Toxicity: Powered by our patented lipid-based formulation, XcellFect overcomes traditional delivery bottlenecks to deliver ultra-high transfection efficiency while maintaining minimal cytotoxicity. Say goodbye to compromised cell viability! Broad Spectrum Compatibility: Designed for versatility, XcellFect works seamlessly across common cell lines and is specially optimized for hard-to-transfect cells. No more struggling with inconsistent results! Multi-RNA Flexibility: Whether you’re working with siRNA, mRNA, miRNA, or other RNA types, XcellFect ensures robust delivery for diverse applications—from gene silencing to therapeutic development. Streamlined Workflow: Just mix Reagent A and B, combine with RNA, and add to cells—no media replacement needed! Compatible with complete culture media, saving you time and simplifying protocols. Ideal For: Gene function studies Therapeutic RNA delivery CRISPR-Cas9 workflows High-throughput screening ransform Your Research Today! contact our team at polydarwin@sinopeg.com to learn more or request a sample. Let XcellFect accelerate your breakthroughs in RNA-based science!

Review Mol Ther. 2017 Jul 5;25(7):1467-1475.  doi: 10.1016/j.ymthe.2017.03.013.  Epub 2017 Apr 13. Lipid Nanoparticle Systems for Enabling Gene Therapies Abstract Genetic drugs such as small interfering RNA (siRNA), mRNA, or plasmid DNA provide potential gene therapies to treat most diseases by silencing pathological genes, expressing therapeutic proteins, or through gene-editing applications.  In order for genetic drugs to be used clinically, however, sophisticated delivery systems are required.  Lipid nanoparticle (LNP) systems are currently the lead non-viral delivery systems for enabling the clinical potential of genetic drugs.  Application will be made to the Food and Drug Administration (FDA) in 2017 for approval of an LNP siRNA drug to treat transthyretin-induced amyloidosis, presently an untreatable disease.  Here, we first review research leading to the development of LNP siRNA systems capable of silencing target genes in hepatocytes following systemic administration.  Subsequently, progress made to extend LNP technology to mRNA and plasmids for protein replacement, vaccine, and gene-editing applications is summarized.  Finally, we address current limitations of LNP technology as applied to genetic drugs and ways in which such limitations may be overcome.  It is concluded that LNP technology, by virtue of robust and efficient formulation processes, as well as advantages in potency, payload, and design flexibility, will be a dominant non-viral technology to enable the enormous potential of gene therapy. Keywords: gene editing;  gene therapy;  genetic drugs;  lipid nanoparticles;  mRNA;  siRNA. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com